Journal of International Oncology››2016,Vol. 43››Issue (11): 812-816.doi:10.3760/cma.j.issn.1673-422X.2016.11.003
Previous ArticlesNext Articles
Zhou Haijing, Yang Liping, Wang Liming, Yan Xiang
Received:
2016-02-25Online:
2016-11-08Published:
2016-11-02Contact:
Yan Xiang E-mail:yanxiang528@sohu.comSupported by:
Science and Technology Major Project of Gansu Province of China (1302FKDA029)
Zhou Haijing, Yang Liping, Wang Liming, Yan Xiang. Anti-hepatocellular carcinoma effect of low dose cyclophosphamide combined with CIK cells in mice[J]. Journal of International Oncology, 2016, 43(11): 812-816.
[1] Chen X, Du Y, Lin X, et al. CD4+CD25+ regulatory T cells in tumor immunity[J]. Int Immunopharmacol, 2016, 34(34): 244-249. DOI: 10.1016/j.intimp.2016.03.009. [2]Madondo MT, Quinn M, Plebanski M. Low dose cyclophosphamide: mechanisms of T cell modulation[J]. Cancer Treat Rev, 2016, 42(42): 3-9. DOI: 10.1016/j.ctrv.2015.11.005. [3]Joshi PS, Liu JQ, Wang Y, et al. Cytokineinduced killer T cells kill immature dendritic cells by TCRindependent and perforindependent mechanisms[J]. J Leukoc Biol, 2006, 80(6): 1345-1353. DOI: 10.1189/jlb.0506305. [4] Wang Y, Liu T, Tang W, et al. Hepatocellular carcinoma cells induce regulatory T cells and Lead to poor prognosis via production of transforming growth factorβ1[J]. Cell Physiol Biochem, 2016, 38(1): 306-318. DOI: 10.1159/000438631. [5] Ke X, Zhang S, Xu J, et al. Nonsmallcell lung cancerinduced immunosuppression by increased human regulatory T cells via Foxp3 promoter demethylation[J]. Cancer Immunol Immunother, 2016, 65(5): 587-599. DOI: 10.1007/s0026201618256. [6] Tao Q, Wang H, Zhai Z. Targeting regulatory T cells in cytokineinduced killer cell cultures (Review)[J]. Biomedical Rep, 2014, 2(3): 317-320. DOI: 10.3892/br.2014.234. [7] Li CH, Kuo WH, Chang WC, et al. Activation of regulatory T cells instigates functional downregulation of cytotoxic T lymphocytes in human breast cancer[J]. Immunol Res, 2011, 51(1): 71-79. DOI: 10.1007/s12026-011-8242-x. [8] Heylmann D, Bauer M, Becker H, et al. Human CD4+CD25+ regulatory T cells are sensitive to low dose cyclophosphamide: implications for the immune response[J]. PLoS One, 2013, 8(12): e83384. DOI: 10.1371/journal.pone.0083384. [9] Zhao J, Cao Y, Lei Z, et al. Selective depletion of CD4+CD25+Foxp3+ regulatory T cells by lowdose cyclophosphamide is explained by reduced intracellular ATP levels[J]. Cancer Res, 2010, 70(12): 4850-4858. DOI: 10.1158/0008-5472.CAN-10-0283. [10] Huang X, Huang G, Song H, et al. Preconditioning chemotherapy with paclitaxel and cisplatin enhances the antitumor activity of cytokine inducedkiller cells in a murine lung carcinoma model[J]. Int J Cancer, 2011, 129(3): 648-658. DOI: 10.1002/ijc.25702. [11] Lutsiak ME, Semnani RT, De Pascalis R, et al. Inhibition of CD4(+)25+ T regulatory cell function implicated in enhanced immune response by lowdose cyclophosphamide[J]. Blood, 2005, 105(7): 2862-2868. DOI: 10.1182/blood2004062410. [12] Ge Y, Domschke C, Stoiber N, et al. Metronomic cyclophosphamide treatment in metastasized breast cancer patients: immunological effects and clinical outcome[J]. Cancer Immunol Immunother, 2012, 61(3): 353-362. DOI: 10.1007/s0026201111063. [13] Wu J, Waxman DJ. Metronomic cyclophosphamide eradicates large implanted GL261 gliomas by activating antitumor Cd8(+) Tcell responses and immune memory[J]. Oncoimmunology, 2015, 4(4): e1005521. DOI: 10.1080/2162402X.2015.1005521. [14] Cerullo V, Diaconu I, Kangasniemi L, et al. Immunological effects of lowdose cyclophosphamide in cancer patients treated with oncolytic adenovirus[J]. Mol Ther, 2011, 19(9): 1737-1746. DOI: 10.1038/mt.2011.113. [15] Le DT, Jaffee EM. Regulatory Tcell modulation using cyclophosphamide in vaccine approaches: a current perspective[J]. Cancer Res, 2012, 72(14): 3439-3444. DOI: 10.1158/00085472.CAN113912. [16] Kochenderfer JN, Wilson WH, Janik JE, et al. Eradication of Blineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19[J]. Blood, 2010, 116(20): 4099-4102. DOI: 10.1182/blood-2010-04-281931. [17] Linette GP, Stadtmauer EA, Maus MV, et al. Cardiovascular toxicity and titin crossreactivity of affinityenhanced T cells in myeloma and melanoma[J]. Blood, 2013, 122(6): 863-871. DOI: 10.1182/blood-2013-03-490565. |
[1] | Yang Mi, Bie Jun, Zhang Jiayong, Deng Jiaxiu, Tang Zuge, Lu Jun.Analysis of the efficacy and prognosis of neoadjuvant therapy for locally advanced resectable esophageal cancer[J]. Journal of International Oncology, 2024, 51(6): 332-337. |
[2] | Chen Hongjian, Zhang Suqing.Study on the relationship between serum miR-24-3p, H2AFX and clinical pathological features and postoperative recurrence in liver cancer patients[J]. Journal of International Oncology, 2024, 51(6): 344-349. |
[3] | Xu Fenglin, Wu Gang.Research progress of EBV in tumor immune microenvironment and immunotherapy of nasopharyngeal carcinoma[J]. Journal of International Oncology, 2024, 51(6): 359-363. |
[4] | Gao Fan, Wang Ping, Du Chao, Chu Yanliu.Research progress on intestinal flora and non-surgical treatment of the colorectal cancer[J]. Journal of International Oncology, 2024, 51(6): 376-381. |
[5] | Fan Zhipeng, Yu Jing, Hu Jing, Liao Zhengkai, Xu Yu, Ouyang Wen, Xie Conghua.Predictive value of changes in inflammatory markers for prognosis in patients with advanced non-small cell lung cancer treated with the first-line immunotherapy plus chemotherapy[J]. Journal of International Oncology, 2024, 51(5): 257-266. |
[6] | Yang Hao, Shi Guidong, Zhang Chengcheng, Zhang Yue, Zhang Liwen, Fu Maoyong.Comparison of efficacy and safety between sintilimab and tislelizumab in neoadjuvant therapy for advanced esophageal squamous cell carcinoma[J]. Journal of International Oncology, 2024, 51(4): 210-216. |
[7] | Sa Qiang, Xu Hangcheng, Wang Jiayu.Advances in immunotherapy for breast cancer[J]. Journal of International Oncology, 2024, 51(4): 227-234. |
[8] | Sun Weiwei, Yao Xuemin, Wang Pengjian, Wang Jing, Jia Jinghao.Exploration of prognostic factors and nomogram construction for advanced non-small cell lung cancer treated with immunotherapy based on hematologic indexes[J]. Journal of International Oncology, 2024, 51(3): 143-150. |
[9] | Liu Yulan, Jing Haiyan, Sun Jing, Song Wei, Sha Dan.Advances in predicting efficacy and prognostic markers of immunotherapy for gastric cancer[J]. Journal of International Oncology, 2024, 51(3): 175-180. |
[10] | Peng Qin, Cai Yuting, Wang Wei.Advances on KPNA2 in liver cancer[J]. Journal of International Oncology, 2024, 51(3): 181-185. |
[11] | Sun Guobao, Yang Qian, Zhuang Qingchun, Gao Binbin, Sun Xiaogang, Song Wei, Sha Dan.Research progress on the histopathological growth patterns of colorectal liver metastasis[J]. Journal of International Oncology, 2024, 51(2): 114-118. |
[12] | Xiang Yuling, Tan Jiajie, Xiong Yuanguo, Zhao Lirong, Li Chen, Zhang Hong.Effects of Anhydroicaritin on the proliferation, migration and apoptosis of hepatocellular carcinoma cells[J]. Journal of International Oncology, 2023, 50(9): 513-519. |
[13] | Cui Tenglu, Lyu lu, Sun Pengfei.Application of radiotherapy combined with immunotherapy in the treatment of head and neck squamous cell carcinoma[J]. Journal of International Oncology, 2023, 50(9): 548-552. |
[14] | Guo Ciliang, Jiang Chunping, Wu Junhua.Gut microbiome and tumor immunotherapy[J]. Journal of International Oncology, 2023, 50(7): 432-436. |
[15] | Li Qingshan, Xie Xin, Zhang Nan, Liu Shuai.Research progress on the application of combining radiotherapy and systemic therapy in breast cancer[J]. Journal of International Oncology, 2023, 50(6): 362-367. |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||